These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 22437409)

  • 1. Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease.
    Torres PA; De Broe M
    Kidney Int; 2012 Jul; 82(1):19-25. PubMed ID: 22437409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium-sensing receptor activation in chronic kidney disease: effects beyond parathyroid hormone control.
    Massy ZA; Hénaut L; Larsson TE; Vervloet MG
    Semin Nephrol; 2014 Nov; 34(6):648-59. PubMed ID: 25498383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium-sensing receptor as a potential modulator of vascular calcification in chronic kidney disease.
    Caudrillier A; Mentaverri R; Brazier M; Kamel S; Massy ZA
    J Nephrol; 2010; 23(1):17-22. PubMed ID: 20091482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism.
    Rodriguez M; Nemeth E; Martin D
    Am J Physiol Renal Physiol; 2005 Feb; 288(2):F253-64. PubMed ID: 15507543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.
    Cunningham J; Locatelli F; Rodriguez M
    Clin J Am Soc Nephrol; 2011 Apr; 6(4):913-21. PubMed ID: 21454719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease.
    Goodman WG
    Semin Dial; 2004; 17(3):209-16. PubMed ID: 15144547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure.
    Cozzolino M; Gallieni M; Brancaccio D; Arcidiacono T; Bianchi G; Vezzoli G
    J Nephrol; 2006; 19(5):566-77. PubMed ID: 17136683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of calcium and phosphate metabolism impairment in chronic kidney disease.
    Cozzolino M; Ciceri P; Volpi EM; Olivi L; Messa PG
    Blood Purif; 2009; 27(4):338-44. PubMed ID: 19295196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
    Bernardor J; De Mul A; Bacchetta J; Schmitt CP
    Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.
    Rodríguez M; Goodman WG; Liakopoulos V; Messa P; Wiecek A; Cunningham J
    Semin Dial; 2015; 28(5):497-507. PubMed ID: 25752650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells.
    Alam MU; Kirton JP; Wilkinson FL; Towers E; Sinha S; Rouhi M; Vizard TN; Sage AP; Martin D; Ward DT; Alexander MY; Riccardi D; Canfield AE
    Cardiovasc Res; 2009 Feb; 81(2):260-8. PubMed ID: 18852253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular changes in chronic renal disease patients with secondary hyperparathyroidism.
    Bortotolotto LA; Costa-Hong V; Jorgetti V; Consolim-Colombo F; Rosa K; Silva BC; Krieger EM; De Lima JJ
    J Nephrol; 2007; 20(1):66-72. PubMed ID: 17347976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the role of calcium-sensing receptor activation.
    Cozzolino M; Mazzaferro S; Messa P
    J Nephrol; 2011; 24 Suppl 18():S38-41. PubMed ID: 21623581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Basic and clinical aspects of calcimimetics. The pathogesis and treatment of secondary hyperparathyroidism].
    Mizobuchi M; Akizawa T
    Clin Calcium; 2008 Jan; 18(1):13-9. PubMed ID: 18175866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.
    Mizobuchi M; Hatamura I; Ogata H; Saji F; Uda S; Shiizaki K; Sakaguchi T; Negi S; Kinugasa E; Koshikawa S; Akizawa T
    J Am Soc Nephrol; 2004 Oct; 15(10):2579-87. PubMed ID: 15466262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological study.
    Filipozzi P; Ayav C; Ngueyon Sime W; Laurain E; Kessler M; Brunaud L; Frimat L
    BMJ Open; 2017 Mar; 7(3):e011482. PubMed ID: 28348181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth muscle cells: mechanisms of action.
    Hénaut L; Boudot C; Massy ZA; Lopez-Fernandez I; Dupont S; Mary A; Drüeke TB; Kamel S; Brazier M; Mentaverri R
    Cardiovasc Res; 2014 Feb; 101(2):256-65. PubMed ID: 24217682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.